ArticlePloS one2025
Evaluating miR-107 and adiponectin as biomarkers in obstructive sleep apnea: Associations with neurotransmitters and metabolic regulation.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond the Apnea-Hypopnea Index: Circulating Biomarkers and Device-Based Metrics for Cardiometabolic Risk Stratification in Obstructive Sleep Apnea.Journal of clinical medicine · 2026Review
- miR-1180-3p as a biomarker of obstructive sleep apnea hypopnea syndrome and its role in chronic intermittent hypoxia-induced vascular injury.Clinics (Sao Paulo, Brazil) · 2026Article
- Chronic Intermittent Hypoxia Promotes Macrophage Inflammation Through Reduction of Adipocyte‑Derived Adiponectin.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to examine the levels of microRNA-107 (miR-107) and its correlation with neurotransmitters (glutamate, serotonin, melatonin) and adiponectin in patients with obstructive sleep apnea (OSA) compared to healthy controls. The results showed that serum levels of miR107, melatonin, and adiponectin were significantly lower in OSA patients compared to controls, while serotonin and glutamate levels were significantly higher. Spearman correlation analysis revealed that in the control group, miR-107 levels were moderately correlated with glutamate (negative) and adiponectin (positive), but these associations were disrupted in the OSA group. Receiver operating characteristic (ROC) curve analysis demonstrated that miR-107 had excellent diagnostic performance, with 100% sensitivity and 89.3% specificity at a cut-off of 3.0 ng/mL. Adiponectin also showed strong diagnostic potential, with 78% sensitivity and 89% specificity. In contrast, serotonin, melatonin, and glutamate exhibited more moderate diagnostic accuracy. These findings suggest that miR-107 and adiponectin could serve as promising biomarkers for diagnosing OSA, and targeting miR-107 to modulate metabolic factors may offer novel therapeutic approaches for improving OSA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.